136.20 +0.05 (0.04%)
After hours: 4:02PM EDT
|Bid||64.45 x 1100|
|Ask||145.00 x 800|
|Day's range||133.95 - 137.55|
|52-week range||77.75 - 167.35|
|PE ratio (TTM)||1,047.69|
|Earnings date||7 Aug 2017 - 11 Aug 2017|
|Forward dividend & yield||N/A (N/A)|
|1y target est||157.83|
Small and large cap stocks are widely popular for a variety of reasons, however, mid-cap companies such as Penumbra Inc (NYSE:PEN), with a market cap of US$5.08b, often get neglectedRead More...
Penumbra Inc (NYSE:PEN), a medical equipment company based in United States, saw a significant share price rise of over 20% in the past couple of months on the NYSE. WithRead More...
Today, I will be analyzing Penumbra Inc’s (NYSE:PEN) recent ownership structure, an important but not-so-popular subject among individual investors. The impact of a company’s ownership structure affects both its short-Read More...
The Alameda, California-based company said it had profit of 15 cents per share. Earnings, adjusted for pretax gains, were 6 cents per share. The results exceeded Wall Street expectations. The average estimate ...
An important component of the broader Medical sector, the Medical Product space consistently grabs attention owing to a string of upsides.
The Alameda, California-based company said it had profit of 25 cents per share. Earnings, adjusted for non-recurring gains, were 10 cents per share. The results topped Wall Street expectations. The average ...
Penumbra (PEN) is seeing favorable earnings estimate revision activity as of late, which is generally a precursor to an earnings beat.
Penumbra (PEN) expects to gain from solid performance by neuro and peripheral vascular arms in Q4. Strong growth across all geographies is likely to drive the top line.
Penumbra, Inc. , a global healthcare company focused on innovative therapies, today announced the presentation of the results of the COMPASS Trial, an independent, prospective, multi-center randomized trial that showed the use of Penumbra’s aspiration system was non-inferior to stent retrievers for patients with acute ischemic stroke.
Penumbra, Inc. , a global healthcare company focused on innovative therapies, today announced results of the company-sponsored PROMISE Study, demonstrating real-world safety and efficacy of the Penumbra System with ACE™68 and ACE™64 Reperfusion Catheters as frontline treatment in patients with acute ischemic stroke using the ADAPT approach.
Penumbra, Inc. , a global healthcare company focused on innovative therapies, today announced key events at the upcoming International Stroke Conference 2018 meeting to be held January 24-26 at the Los Angeles Convention Center.
The results of the independent, prospective, randomized controlled COMPASS Trial (A Comparison of Direct Aspiration vs. Stent Retriever as a First Approach) will be presented by J. Mocco, M.D., M.S., Ichan School of Medicine at Mount Sinai, New York. The multi-center COMPASS Trial compared mechanical thrombectomy with the ADAPT (A Direct Aspiration First Pass Technique) approach to stent retrievers in patients presenting with acute ischemic stroke (AIS) within six hours of symptom onset.
Penumbra's (PEN) joint venture with Sixense Enterprises indicates formation of a leading digital health platform in the field of virtual reality technology.
Penumbra, Inc. , a global healthcare company focused on innovative therapies, today announced it has entered into a joint venture called MVI Health Inc., for the purpose of exploring healthcare applications of virtual reality technology with Sixense Enterprises, Inc.
Penumbra shows rising price performance, earning an upgrade to its IBD Relative Strength Rating from 79 to 83.
Jim Cramer examined the dip in shares of Penumbra, a medical device maker focused on treating strokes and aneurysms by removing blood clots.